ReviewInflammopharmacology2026
Plant-derived indole alkaloids in chronic inflammatory diseases: molecular mechanisms, therapeutic potential and translational challenges.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic inflammatory diseases are major global health challenges driven by persistent oxidative stress and dysregulated immune signalling. Plant-derived indole alkaloids are structurally diverse metabolites found in medicinal plants, fungi and marine organisms; that exhibit potent multi-target anti-inflammatory and antioxidant activities.
aimThis review integrates current evidence on the chemistry, sources and mechanistic pathways of plant-derived indole alkaloids, emphasizing their modulation of key inflammatory axes, including NF-κB, JAK/STAT, MAPK, PI3K/AKT, NLRP3 inflammasome and AhR signalling.
methodsA thorough search of PubMed, Scopus and Google Scholar databases was conducted up to December 2025. Eligible studies included preclinical, clinical and review articles addressing the effects of indole alkaloids on inflammatory mediators, oxidative stress markers and disease endpoints.
resultsIndole alkaloids have been proven to suppress pro-inflammatory mediators; like TNF-α, IL-1β, IL-6, NO, PGE₂, COX-2 and iNOS; while enhancing antioxidant defences and cytoprotective responses. Representative scaffolds have demonstrated promising protective effects in colitis, osteoarthritis, COPD, atherosclerosis, chronic kidney disease and inflammation-driven cancers through restoration of epithelial and endothelial barriers, immune-cell reprogramming and rebalancing of organ-specific crosstalk. Monoterpenoid and tryptophan-derived indole alkaloids particularly integrated AhR and NF-κB/STAT3 pathways, supporting microbiota- and organ-selective therapeutic prospects.
conclusionsPlant-derived indole alkaloids emerge as promising yet underexploited multi-target scaffolds for chronic inflammatory diseases, primarily supported by preclinical evidence. Future advances in synthetic biology, metabolomics and rational hybrid design are essential to overcome translational barriers and enable clinically scalable development of this chemotype.
Indexed as
Identifiers
42009998What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.